Owlstone Medical last week announced that it has forged a partnership with Thermo Fisher Scientific‘s (NYSE:TMO) to advance non-invasive breath sampling in disease detection.
Through the agreement, both companies will integrate the Thermo Scientific Q Exactive GC Hybrid Quadrupole-Orbitrap MassSpectrometer into Owlstone Medical’s Breath Biopsy platform. The collaboration will hopefully qualify the mass analyzer for detecting biomarkers to become a part of Owlstone Medical’s biomarker discovery process.
Get the full story on our sister site, Drug Delivery Business.
Filed Under: Drug Discovery and Development
Tell Us What You Think!
You must be logged in to post a comment.